FDA批准Tretten（重组）凝血因子XⅢ A亚单位，这是首个常规用于患有被称为先天性凝血因子XⅢ A-亚单位缺失这种罕见的凝血障碍的成人和儿童预防出血的重组产品。

 先天性凝血因子XⅢ缺乏症是一种极为罕见的遗传性疾病。XⅢ因子由A和B两个亚单位组成，因子XⅢ缺乏症通常是由A亚单位缺失引起的。

 在77名先天性凝血因子XⅢ A亚单位缺失患者中对Tretten的效果作了研究。Tretten每月给药，90%的患者能有效预防出血。该药是一种罕见病药，由诺和诺德丹麦公司生产，美国公司配售。

FDA approves Tretten to treat rare genetic clotting disorder

The U.S. Food and Drug Administration today approved Tretten, Coagulation Factor XIII A-Subunit (Recombinant), the first recombinant product for use in the routine prevention of bleeding in adults and children who have a rare clotting disorder, known as congenital Factor XIII A-subunit deficiency.

Congenital Factor XIII deficiency is an extremely rare genetic disorder. Patients with this deficiency do not make enough Factor XIII, a protein that circulates in the blood and is important for normal clotting. Factor XIII is composed of two subunits, A and B. Factor XIII deficiency is usually caused by a deficiency of the A-subunit.

“The approval of this product provides another therapeutic option for the prevention of bleeding in patients with Factor XIII A-subunit deficiency,” said Karen Midthun, M.D., director of the FDA’s Center for Biologics Evaluation and Research. “Without treatment, people with this rare condition are at risk for serious and life-threatening bleeding.”

Tretten is a recombinant analogue of the human Factor XIII A-subunit that is produced in yeast cells and then further purified. It is a sterile freeze-dried-powder to be reconstituted with diluent and injected intravenously. Tretten can be administered by a physician or be self-administered.

The effectiveness of Tretten was studied in 77 patients with congenital Factor XIII A-subunit deficiency. Tretten was effective in preventing bleeding in 90 percent of the patients when given monthly. Some of the side effects reported in this study were headache, pain in the extremities and pain at injection site. No individual in the trial developed abnormal clots.

Tretten received orphan-drug designation for this use by the FDA because it is intended for treatment of a rare disease or condition.

Tretten is made by Novo Nordisk A/S, Denmark, and is distributed by Novo Nordisk, Inc., USA.

For more information:

Blood & Blood Products

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

免责声明： 

      本文仅供专业人士学术交流探讨，不作为诊疗及用药依据。 

      如有侵权，请联系我们删除